机译:在复发/难治性CNS淋巴瘤中,Ibrutinib基组合治疗的第1B期试验
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Human Oncol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Human Oncol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Human Oncol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Marie Josee &
Henry R Kravis Ctr Mol Oncol 1275 York Ave New York;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Marie Josee &
Henry R Kravis Ctr Mol Oncol 1275 York Ave New York;
Mem Sloan Kettering Canc Ctr Dept Radiol 1275 York Ave New York NY 10021 USA;
Mem Sloan Kettering Canc Ctr Dept Epidemiol &
Biostat New York NY 10021 USA;
Mem Sloan Kettering Canc Ctr Dept Epidemiol &
Biostat New York NY 10021 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
Mem Sloan Kettering Canc Ctr Dept Neurol 1275 York Ave New York NY 10065 USA;
机译:在复发/难治性CNS淋巴瘤中,Ibrutinib基组合治疗的第1B期试验
机译:组合免疫疗法作为难治性或复发性CNS淋巴瘤的非化疗替代品
机译:克唑替尼用于复发或难治性间变性淋巴瘤激酶阳性的间变性大细胞淋巴瘤的I / II期研究和克唑替尼用于复发或难治性神经母细胞瘤的I期研究:多中心单臂开放标签试验的研究方案
机译:Matexafin-Lutetium介导的患者局部复发前列腺癌患者的术语I阶段试验
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:基于依鲁替尼的联合疗法治疗复发/难治的中枢神经系统淋巴瘤的1b期临床试验
机译:利妥昔单抗,氟达拉滨和米托蒽醌联合治疗初治的利妥昔单抗,复发/难治性滤泡性非霍奇金淋巴瘤的高肿瘤负担:成人淋巴瘤研究小组(GELA)的多中心2期试验)和白血病和其他血液疾病的西东部组织(GOELAMS)。